News & Presentations

UPCOMING EVENTS

Date	Title	Documents
July 20, 2021	OIS European Innovation Showcase	Add Files OIS European Innovation Showcase 1.3 MB
June 21, 2021	Corporate Presentation – June	Add Files Corporate Presentation – June 1.6 MB
March 11, 2021	OIS Dry Eye Innovation Showcase Presentation	Add Files OIS Dry Eye Innovation Showcase Presentation 1 MB

Date	Title and Summary	Additional Formats
Toggle SummaryOctober 22, 2009	Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue	View HTML Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study 22 KB
Toggle SummaryOctober 26, 2009	Biocentury - RhoKing Glaucoma	View HTML
Toggle SummaryMarch 7, 2011	Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio Financing Underscores Strong Clinical Progress and Positive Data in Lead Program	View HTML Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio 24 KB
Toggle SummaryApril 12, 2011	American Journal of Ophthalmology - Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension	View HTML